Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

Core Viewpoint - Hims & Hers Health has experienced a significant decline in stock value, dropping 75.50% from its peak due to a lawsuit from Novo Nordisk regarding the marketing of unapproved drugs [1][2][5] Company Performance - Hims & Hers Health's stock reached an all-time high of $64.65 on May 16, 2025, but has since fallen dramatically [1] - The company is expected to report record quarterly revenue of $619 million on February 23, with analysts predicting a return to positive earnings per share (EPS) [3] Legal Challenges - Novo Nordisk filed a lawsuit against Hims & Hers on February 9, accusing the company of unlawfully marketing unapproved versions of its semaglutide medicines [2] - The lawsuit aims to protect Novo Nordisk's patents and seeks to permanently ban Hims & Hers from selling the infringing products [2] Analyst Sentiment - Despite the recent stock decline, analysts remain bullish on Hims & Hers, with expectations of a near-term price reversal due to the stock being considered oversold, as indicated by a Relative Strength Index (RSI) of 16.87 [4][5] - The average 12-month price target for Hims & Hers implies nearly 150% potential upside from current levels [5]